Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG C34001

Title
An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies
Principal Investigator
Adam M Petrich
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG C34001
Purpose
Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.
Overview
This is the first time that TAK-659 will be studied in humans. Experiments in animals have been performed and are continuing to be used to help guide the safe administration of TAK-659 in humans. However, only by studying the drug in patients will the side effects, risks, and the best way to dose TAK-659 be determined.
Eligibility
Some of the eligibility criteria include:
  • Participants in this study must have a form of solid tumor cancer or lymphoma in the first part of the study and the study doctor would have to determine that there is no longer a standard treatment that will be effective. In the second part of the study, participants must have Chronic Lymphocytic Leukemia (CLL) or Diffuse Large B Cell Lymphoma (DLBCL)
  • Participants must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
All participants in the study will take the study drug every day by mouth in tablet form. The study drug is taken during periods that last for 28 days, called “cycles.” Participation could last approximately 12 months, but the number of cycles depends on the severity of any discomforts and side-effects participants may experience and how (or if) their cancer responds to the study drug. A patient may receive more than 12 cycles of treatment if the investigator determines that the patient is benefiting from this investigational drug.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Adam M Petrich

last updated: 01-Nov-14 05:21 AM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.